secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001157523-22-001032
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports Q2 net loss $0.32/sh; positive EDG-5506 BMD interim data
-------------------------------------------------------------------------

- Cash and equivalents $248.4M as of June 30; expected to fund operations through end of 2024.
- Net loss $16.1M ($0.32/sh) for Q2 2022 vs $14.7M ($0.30/sh) prior quarter.
- ARCH study: CK reduced 30%, TNNI2 reduced 68% after 2 months of EDG-5506 10 mg daily.
- Enrolling CANYON Phase 2 trial of EDG-5506 in BMD; plan to start Phase 2 in DMD in 2022.
- Preclinical EDG-002 program for HCM advancing; IND-enabling studies planned in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322001032/0001157523-22-001032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322001032/a52801668.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer